FDA Clears Edoxaban for Reduction of Stroke in Non-Valvular Atrial Fibrillation, Venous Thromboembolism
Savaysa (edoxaban) tablets from Daiichi Sankyo Co. Ltd. are an oral, once-daily selective factor Xa-inhibitor to reduce the risk of stroke
The silence is deafening. And since radiology associations, physician groups and vendors have yet...
57 min 25 sec ago
The America College of Cardiology has released its list of key late-breaking clinical trials at the...
1 week 20 hours ago
As editor of DAIC, I keep a close watch on trends in cardiovascular technology and try to predict...
4 weeks 22 hours ago
Sorry there is no data available